ACHE and Alzheimer disease: Based on these results, Sarathlal et al. concluded that (1) RSG upregulates neurotrophic factors like BDNF and improves memory and cognition in an AD-mouse model, (2) a nanoformulated carrier system offers neuroprotection at lower doses compared to the free drug form, and (3) RSG treatment can lower AChE activity, supporting the drug as a potential AD therapeutic [12].